Why Celcuity Stock Popped on Monday
Key Points
It's clinical-stage at the moment, but might not stay that way for much longer.
The company's leading drug candidate could win approval in less than two months.
- 10 stocks we like better than Celcuity ›
One of the livelier biotech stocks on the market Monday was Celcuity (NASDAQ: CELC), which saw its share price leap nearly 4% higher thanks to the initiation of coverage by an analyst. That initial report on the company was quite bullish, hence the positive investor reaction.
On the brink of a decision
Well before market open, Citizens pundit Silvan Turkcan launched his tracking of Celcuity stock. He rates the clinical-stage biotech a market outperform (i.e., buy) and has set a $150-per-share price target. That's nearly 20% above the company's latest closing level and is one of the higher price targets among analysts following Celcuity.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Image source: Getty Images.
According to reports, Turkcan's analysis centers -- not surprisingly -- on gedatolisib, its investigational drug that targets advanced breast cancer. The medication is less than two months away from the date the Food and Drug Administration (FDA) has set to complete its review of the company's New Drug Application (NDA) for it.
The analyst pointed out that gedatolisib, one of the more promising oncology drugs currently under review, could eventually be approved for other indications besides breast cancer. That alone would give not only significant value to the drug but also to its developer.
A hot biotech in a hot segment
Any potential blockbuster cancer drug won't go ignored by market players for long. Celcuity is on many a biotech investor's radar due to gedatolisib's sky-high potential and its fine shot at FDA approval in the very near future.
While the stock is expensive, its leading drug candidate's potential alone could further increase its value. I'd still be a buyer of this stock.
Should you buy stock in Celcuity right now?
Before you buy stock in Celcuity, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Celcuity wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $498,522!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,276,807!*
Now, it’s worth noting Stock Advisor’s total average return is 983% — a market-crushing outperformance compared to 200% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of April 27, 2026.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
